PBMs

Biosimilars are poised to disrupt the drug chain in 2023. What do brokers and plan sponsors need to know?

How should pharma companies plan for if their drugs will be included in accumulator or maximizer programs? Use our interactive checklist.

How can you inject more transparency into your pharmacy plan? Watch the recording of our webinar.

Read what issues the HR leaders at Equinox, Kyndryl, and Phreesia are citing as the biggest benefit challenges this year.

Truveris’ Pharmacy Benefits Glossary of Terms provides important definitions and context to help navigate the pharmacy benefits landscape.

If you work in the pharmacy ecosystem, you’ve probably heard buzz around “biosimilars.” What should you know about this innovative type of medication?

Watch Truveris’ exclusive Human Resources round table, originally recorded on June 8th, 2022.

Plan sponsors are looking for new ways to contain specialty costs. How should they evaluate new copay assistance strategies?

Truveris covers exactly how leading employer groups and their brokers are implementing copay maximizers and accumulators.

As pharmacy costs increase, what are strategies plan sponsors can take to control specialty pharmacy spend?

Read Sally Welborn’s POV piece on the misaligned incentives at play in the pharmacy benefits ecosystem – and what it means for plan sponsors.

How are copay maximizers and alternative funding impacting plans – and members? Watch our on-demand webinar to learn more.

Truveris announces the launch of oneRx, the only drug price transparency solution that helps members navigate their pharmacy benefits.

After you procure a strong PBM contract, make sure your members are engaging with the plan productively.

See how Truveris has helped employers of all sizes procure their pharmacy benefits.

By framing your pharmacy benefits strategy around these three pillars, you’ll construct a more cost-effective, accessible pharmacy program.

While a pharmacy benefits contract is a powerful lever for managing spend, it is also very complicated, with variables impacted by market and industry dynamics.

What is member-centricity? Why should plan sponsors and brokers strive to reimagine their pharmacy program with members in mind?

340B is increasingly a part of the pharmacy conversation. How should stakeholders react to the program?

Many gene therapy products are soon to be released to the market. What do payers need to know about these highly-expensive specialty drugs?

What is the future of the PBM landscape? Listen to Truveris CEO, Nanette Oddo, opine on the shifts she’s seeing in the pharmacy ecosystem.

Several states have passed legislation that prohibits the use of copay accumulator adjustment programs. How does this affect your organization?

Understanding the ins and outs of drug formularies is essential to making an informed decision on which PBM to select for your members.

Generic versions of brand name medications are not all the same. Understanding their differences and their implications on MAC pricing is critical for choosing the most cost-effective PBM.

Watch Truveris’ webinar to learn more about how you can better manage a self-funded specialty pharmacy program.

Pharmacy Benefits Managers, also referred to as PBMs, are the intermediaries between every stakeholder in the pharmacy ecosystem.

Why type of plan sponsor could benefit from carving out their pharmacy plan?

Get up to speed on all the industry-speak and confusing jargon that surrounds the work of PBMs.

In October of 2017, Anthem Inc. announced its launching of IngenioRx, an in-house pharmacy benefits manager (PBM).